Innocrin Pharmaceuticals Inc. To Present Interim Results From Its Phase 1/2 Prostate Cancer Clinical Study And Preclinical Results That Demonstrate VT-464 Efficacy In A Clinically-Relevant Enzalutamide-Resistant Mouse Model

Innocrin Pharmaceuticals, Inc. (www.innocrinpharma.com), a privately held pharmaceutical company that focuses on the discovery and development of best-in-class, small molecule CYP17 lyase inhibitors announces that results from clinical and preclinical studies with its Phase 2 clinical lead, VT-464, will be presented at the 2015 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, taking place from February 26 - 28, 2015 in Orlando, Florida.

Help employers find you! Check out all the jobs and post your resume.